Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs

This cross-sectional study examines how information on overall survival benefits of novel cancer drug indications is communicated in labeling

MVP: Meta Visual Prompt Tuning for Few-Shot Remote Sensing Image Scene Classification

Vision Transformer (ViT) models have recently emerged as powerful and versatile models for various visual tasks. Recently, a work called PMF has achieved promising results in few-shot image classification by utilizing pre-trained vision transformer models. However, PMF employs full fine-tuning for learning the downstream tasks, leading to significant overfitting and storage issues, especially in the remote sensing domain. In order to tackle these issues, we turn to the recently proposed parameter-efficient tuning methods, such as VPT, which updates only the newly added prompt parameters while keeping the pre-trained backbone frozen. Inspired by VPT, we propose the Meta Visual Prompt Tuning (MVP) method. Specifically, we integrate the VPT method into the meta-learning framework and tailor it to the remote sensing domain, resulting in an efficient framework for Few-Shot Remote Sensing Scene Classification (FS-RSSC). Furthermore, we introduce a novel data augmentation strategy based on patch embedding recombination to enhance the representation and diversity of scenes for classification purposes. Experiment results on the FS-RSSC benchmark demonstrate the superior performance of the proposed MVP over existing methods in various settings, such as various-way-various-shot, various-way-one-shot, and cross-domain adaptation.Comment: SUBMIT TO IEEE TRANSACTION

Posture-specific breathing detection

Human respiratory activity parameters are important indicators of vital signs. Most respiratory activity detection methods are naïve abd simple and use invasive detection technology. Non-invasive breathing detection methods are the solution to these limitations. In this research, we propose a non-invasive breathing activity detection method based on C-band sensing. Traditional non-invasive detection methods require special hardware facilities that cannot be used in ordinary environments. Based on this, a multi-input, multi-output orthogonal frequency division multiplexing (MIMO-OFDM) system based on 802.11n protocol is proposed in this paper. Our system improves the traditional data processing method and has stronger robustness and lower bit relative error. The system detects the respiratory activity of different body postures, captures and analyses the information, and determines the influence of different body postures on human respiratory activity

Contactless finger tapping detection at C band

The rapid finger tap test is widely used in clinical assessment of dyskinesias in Parkinson’s disease. In clinical practice, doctors rely on their clinical experience and use the Parkinson’s Disease Uniform Rating Scale to make a brief judgment of symptoms. We propose a novel C-band microwave sensing method to evaluate finger tapping quantitatively and qualitatively in a non-contact way based on wireless channel information (WCI). The phase difference between adjacent antennas is used to calibrate the original random phase. Outlier filtering and smoothing filtering are used to process WCI waveforms. Based on the resulting signal, we define and extract a set of features related to the features described in UPDRS. Finally, the features are input into a support vector machine (SVM) to obtain results for patients with different severity. The results show that the proposed system can achieve an average accuracy of 99%. Compared with the amplitude, the average quantization accuracy of the phase difference on finger tapping is improved by 3%. In the future, the proposed system could assist doctors to quantify the movement disorders of patients, and it is very promising to be a candidate for clinical practice

Investigation of hot spring gas components and soil gas fluxes in Arxan Holocene volcanic field, Inner Mongolia, NE China

The latest research results show that there is a unified magma system and heating channel beneath the Arxan volcanic field, indicating a potential risk of eruption. The Arxan volcanic field features multiple gas emission sites (e.g., Jinjianggou hot springs and Yinjianggou hot springs) and exhibits strong hydrothermal activity. In this study, measurements of the hot spring gas composition and soil CO2 flux in the Arxan Holocene volcanic field were conducted, and the results were combined with previous research results to analyze the degassing characteristics of this region. The results show that the volcanic gases in the Arxan volcanic field are composed of 0.07%–1.09% CO2, 0.33–12 ppm CH4, 1.57–53 ppm H2, 800–30,241 ppm He, and 1.14%–1.86% Ar. The He content in this area is notably higher than that in other dormant volcanoes in China. This difference is possibly caused by U–Th decay in the Mesozoic granodiorite and acidic volcanic rocks in the study area, which can produce substantial radiogenic He. The soil gas concentrations near the Jinjianggou and Yinjianggou hot springs are higher than those of two Holocene volcanoes. The peak CO2 concentration in the soil near the Jinjianggou hot spring can reach 35,161 ppm. The single-site soil microseepage CO2 flux in the Arxan volcanic field is 4.66–107.18 g m−2 d−1, and the estimated annual CO2 emission flux from the volcanic field to the atmosphere is 0.63 × 105 t, which also demonstrates that soil CO2 flux of Arxan volcano is comparable to the soil CO2 emission level of the Iwojima volcano

Dual-emission ratio fluorescence for selective and sensitive detection of ferric ions and ascorbic acid based on one-pot synthesis of glutathione protected gold nanoclusters

A fluorometric method was proposed for the determination of Fe3+and ascorbic acid (AA) based on blue and red dual fluorescence emissions of glutathione (GSH) stabilized-gold nanoclusters (AuNCs). AuNCs were synthesized from GSH and tetrachloroauric acid. The fluorescence peaks of AuNCs were at 425 nm and 585 nm, respectively. In the presence of Fe3+, the fluorescence peak at 425 nm can be enhanced and that at 585 nm can be quenched. There is a good linear relationship between the fluorescence intensity ratio for the 425 and 585 nm peaks (F425/F585) and the concentration of Fe3+in the range of 0.75-125 µM. However, when AA was added to the AuNCs-Fe3+system, the value ofF425/F585decreased consistently with the concentration of AA in the range of 0.25-35 µM. The limit of detection for Fe3+and AA was 227 and 75.8 nM, respectively. The interaction between AuNCs and Fe3+can induce the ligand-metal charge transfer (LMCT) effect leading to the fluorescence increment at 425 nm, while AA can reduce Fe3+to Fe2+. The production of Fe2+can not enhance or quench the fluorescence of AuNCs. By comparison with previous literature, the AuNCs prepared here show two fluorescence peaks without additional fluorescence labels. Furthermore, the method was successfully applied in the determination of Fe3+and AA in some real samples, such as water, human serum and tablets

Overall survival benefits of cancer drugs approved in China from 2005 to 2020

Importance: Of approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies authorized in China is not available. Objective: To characterize the clinical benefits of cancer drugs approved in China, as defined by the availability and magnitude of statistically significant overall survival (OS) results. Design, Setting, and Participants: This mixed-methods study comprising a systematic review and cross-sectional analysis identified antineoplastic agents approved in China between January 1, 2005, and December 31, 2020, using publicly available data and regulatory review documents issued by the National Medical Products Administration. The literature published up to June 30, 2021, was reviewed to collect results on end points used in pivotal trials supporting cancer drug approvals. Main Outcomes and Measures: The primary outcome measure was a documented statistically significant positive OS difference between a new cancer therapy and a comparator treatment. Secondary outcome measures were the magnitude of OS benefit and other primary efficacy measures in pivotal trials. Results: Between 2005 and 2020, 78 cancer drugs corresponding to 141 indications were authorized in China, including 20 drugs (25.6%) (for 30 indications) approved in China only. Of all indications, 26 (18.4%) were evaluated in single-arm or dose-optimization trials, most of which were authorized after 2017. By June 30, 2021, 34 drug indications (24.1%) had a documented lack of OS gain. For 68 indications (48.2%) that had documented evidence of OS benefit, the median magnitude of OS improvement was 4.1 (range, 1.0-35.0) months. After a median follow-up of 1.9 (range, 1.0-11.1) years from approval, OS data for 13 indications (9.2%) were either not reported or were still not mature. Fewer than one-third of cancer drug indications approved in China only had documented evidence of OS benefits (9 of 30 [30.0%]), whereas more than one-half of the cancer drug indications also available in the US or Europe had OS benefits (59 of 111 [53.1%]). Conclusions and Relevance: In this study, almost half of cancer drug indications approved in China had demonstrated OS gain. With the increase of cancer drug approvals based on single-arm trials or immature survival data in recent years, these findings highlight the need to routinely monitor the clinical benefits of new cancer therapies in Chin

Noninvasive suspicious liquid detection using wireless signals

Conventional liquid detection instruments are very expensive and not conducive to large-scale deployment. In this work, we propose a method for detecting and identifying suspicious liquids based on the dielectric constant by utilizing the radio signals at a 5G frequency band. There are three major experiments: first, we use wireless channel information (WCI) to distinguish between suspicious and nonsuspicious liquids; then we identify the type of suspicious liquids; and finally, we distinguish the different concentrations of alcohol. The K-Nearest Neighbor (KNN) algorithm is used to classify the amplitude information extracted from the WCI matrix to detect and identify liquids, which is suitable for multimodal problems and easy to implement without training. The experimental result analysis showed that our method could detect more than 98% of the suspicious liquids, identify more than 97% of the suspicious liquid types, and distinguish up to 94% of the different concentrations of alcohol

Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020

BACKGROUND: Perceived delays in cancer drug approvals have been a major concern for policymakers in China. Policies have been implemented to accelerate the launch of new cancer drugs and indications. This study aimed to assess similarities and differences between China and the United States in the approvals, timing, and clinical benefit evidence of cancer drug indications between 2001 and 2020. METHODS: This study retrospectively identified all cancer drugs and indications approved in both China and the United States from January 1st, 2001 to December 31, 2020, and described differences in approval times as well as in submission and review times. Information on the availability of overall survival benefit evidence by December 31, 2020, was collected. Univariate and multiple logistic regression analyses were used to assess whether evidence of benefit and other factors affected the propensity and timing of approvals of cancer drug indications in China. FINDINGS: Between 2001 and 2020, 229 indications corresponding to 145 cancer drugs approved in the United States were identified. Of those, 80 indications (34.9%) were also approved in China by the end of 2020. Cancer drug indications were approved in China at a median of 1273.5 days after approval in the United States. The median submission and review time differences for cancer drug indications in China were 1198.0 days and 180.0 days respectively. Submission time differences accounted for most of the approval time differences (p < 0.001). Indications supported by overall survival benefit evidence had shorter median review time differences (145.0 days) than those without such evidence (235.0 days, p = 0.008). Indications with overall survival benefit evidence were 3.94 times more likely to be approved in China compared to those without such evidence (p = 0.001), controlling for approval year, cancer type, and the prevalence of cancer by site. INTERPRETATION: FDA-approved cancer drug indications demonstrating a survival benefit were more likely to receive approvals in China with shorter regulatory review times compared to indications without such evidence. Given that manufacturer submission times were the main driver of cancer drug approval times in China, factors influencing submission timing should be explored. FUNDING: No funding